Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
273.94
-2.44 (-0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
2 Top Dividend Stocks You Can Buy and Hold Forever
June 17, 2021
Both of these companies raised their dividend payouts even amid the pandemic.
Via
The Motley Fool
Topics
Economy
Exposures
Economy
Should You Buy Biotech ETFs Now?
June 16, 2021
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...
Via
Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
June 14, 2021
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
3 Promising Oncology Stocks To Consider Adding To Your Portfolio
June 14, 2021
With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.
Via
Talk Markets
Market Briefing For Tuesday, Jun. 8
June 08, 2021
Benign market behavior generally persists; as an out-of-the-box rally effort to start Monday was reversed, as is typical since traders want a pullback first.
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
Exposures
Product Safety
Expert Ratings for Amgen
June 07, 2021
Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 0 0...
Via
Benzinga
Price Over Earnings Overview: Amgen
June 07, 2021
Looking into the current session, Amgen Inc. (NASDAQ:AMGN) is trading at $236.47, after a 0.16% decrease. Over the past month, the stock fell by 6.19%, but over the...
Via
Benzinga
Amgen's Sotorasib is First KRAS Inhibitor to Show Overall Survival Benefit in Lung Cancer With KRAS Mutations
June 07, 2021
Amgen Inc (NASDAQ: AMGN) presented data on overall survival from the Phase 2 results of the CodeBreaK 100 clinical study for Lumakras (sotorasib) in previously...
Via
Benzinga
What Does Amgen's Debt Look Like?
June 07, 2021
Shares of Amgen (NASDAQ:AMGN) moved higher by 2.79% in the past three months. Before we understand the importance of debt, let us look at how much debt Amgen has. Amgen...
Via
Benzinga
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
June 05, 2021
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to...
Via
Talk Markets
This Is Why Amgen's New Cancer Drug Could Be Huge
June 02, 2021
The speedy approval of Lumakras could drive growth for years to come.
Via
The Motley Fool
Exposures
Product Safety
Baidu And JD.com Lead The Nasdaq Higher Tuesday
June 01, 2021
U.S. indices had a mixed day of trading Tuesday as concerns over inflation and yields, as well as a rotation out of tech and software names, have c...
Via
Benzinga
Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders
June 01, 2021
Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-...
Via
Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
May 28, 2021
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras...
Via
Benzinga
Exposures
Product Safety
Boeing, Intel Lead The DIA Higher Thursday
May 27, 2021
U.S. indices were trading higher Thursday following better-than-expected U.S. jobless numbers as well as reports that President Joe Biden will...
Via
Benzinga
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
May 27, 2021
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday.
Via
Investor's Business Daily
Exposures
COVID-19
2 Great Income Stocks to Buy Right Now
May 27, 2021
You won't be paying much of a premium for either of these dividend stocks.
Via
The Motley Fool
Tesla And Comcast Lead The QQQ Higher Wednesday
May 26, 2021
U.S. indices had a mixed day of trading as traders and investors weigh Wednesday's earnings reports. Concerns over inflation and yields, a...
Via
Benzinga
Microsoft, Apple, Disney Lead The Dow Jones Higher Monday
May 24, 2021
U.S. indices were trading higher throughout Monday's session amid a rebound in tech names and strength in reopening plays. Here's how ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
'Fast Money' Traders Weigh In On IBB And Gilead
May 21, 2021
On CNBC's "Fast Money," Tim Seymour spoke about a possible break out in iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). He said traders should be defensive in a high...
Via
Benzinga
2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement
May 21, 2021
Here's why you should consider buying into these two companies for the long run.
Via
The Motley Fool
Exposures
COVID-19
Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis
May 20, 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen...
Via
Benzinga
Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report
May 17, 2021
The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel,...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
May 14, 2021
AbCellera stock crumbled Friday after the company guided to lower royalties from Covid treatment partner Eli Lilly in the second quarter.
Via
Investor's Business Daily
EXCLUSIVE: Sree Batchu On The Power Of The Los Angeles MedTech Ecosystem, Why You Should Care
May 11, 2021
To put it simply, the pandemic accelerated emerging trends in medicine: more and more, there is a demand for the disruption of existing health care infrastructures. “While...
Via
Benzinga
Stocks Going Ex Dividend In May 2021
May 10, 2021
Here's a list that contains many dividend-paying companies, lots with market caps over $500 million, and many with yields over 2%.
Via
Talk Markets
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
May 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.